| Product Name | NS-304 (Selexipag; ACT-293987) |
|---|---|
| CAS | 475086-01-2 |
| Formula | C26H32N4O4S |
| MW | 496.62 |
| Appearance | White to yellow powder |
| Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
|---|---|---|---|---|
| 1 mg | 3-5days | ¥300.00 | Visible after login | |
| 5 mg | 3-5days | ¥500.00 | Visible after login | |
| 10 mg | 3-5days | ¥800.00 | Visible after login |
| Product Name | NS-304 (Selexipag; ACT-293987) |
|---|---|
| CAS | 475086-01-2 |
| Formula | C26H32N4O4S |
| MW | 496.62 |
| Appearance | White to yellow powder |
Selexipag, also known as ACT-293987 and NS-304, is a a first-in-class orally available selective non-prostanoid IP receptor agonist, which is currently in development by Actelion as a treatment of pulmonary arterial hypertension. Selexipag and its active metabolite, ACT-333679, are agonists at the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.